Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced new preclinical data from studies evaluating gene therapies, termed… Read More »Opus Genetics (Raleigh, North Carolina) has announced new preclinical data from studies evaluating gene therapies for OPGx-001 and OPGx-002.
Researchers in the Diabetic Retinopathy Clinical Research (DRCR) Retina Network has reported that the treatment of moderate vision loss due to diabetic macular edema found… Read More »Aflibercept monotherapy or “bevacizumab first” for diabetic macular edema assessed the evidence on visual outcomes and costs to the healthcare system.
At least two independent reports on the treatment of VN (voretigene neparvovec) for RPE65-LCA2 has identified retinal atrophic changes on fundus autofluorescence images, following sub-retinal… Read More »Real-word data from voretigene neparvovec treatment of RPE65-LCA2 reports retinal atrophy in Germany and US studies.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the July 28th, 2022 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »July 28th, 2022 “EURETINA-Brief”© Issue No. 258
LumiThera Inc., based in Seattle, WA has showed summary trial data on photo-biomodulation, termed “LIGHTSITE II” study, conducted by a multi-centre clinical trial in dry… Read More »LumiThera Inc., (Seattle, Washington) shows trial data on photo-biomodulation (PBT) for the treatment of dry AMD.
Researchers based at the NEI’s Ophthalmic Genomics Laboratory, National Eye Institute, Bethesda, have reported anomalous TIMP3 variants with altering signal peptide function, distinct from classic Sorsby… Read More »Atypical TIMP3 defects may present a distinct disease mechanism of Sorsby Fundus Dystrophy.
A research team based at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, have reported a new NEI VFQ-25C aimed at calibrating a… Read More »A new NEI VFQ-25C has reported valuable changes to enable comparison of patient-reported outcome measures.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the July 6th, 2022 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »July 6th, 2022 “EURETINA-Brief”© Issue No. 257
REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company, based in Rockville, Maryland, has reported positive interim data from an ongoing Phase II “ALTITUDE” trial of… Read More »Regenxbio Inc.’s gene therapy treatment (RGX-314) for diabetic retinopathy (DR) reports positive interim data from Phase II.
A research team based at the Institute of Genetic Epidemiology, Medical University of Innsbruck, Austria, have shown that the relative telomere length (RTL) is associated… Read More »Relative telomere length (RTL) appears to be associated with age-related macular degeneration in women but not in men.